Your browser doesn't support javascript.
loading
Innate Immune Invisible Ultrasmall Gold Nanoparticles-Framework for Synthesis and Evaluation.
Zhu, Geyunjian Harry; Azharuddin, Mohammad; Islam, Rakibul; Rahmoune, Hassan; Deb, Suryyani; Kanji, Upasona; Das, Jyotirmoy; Osterrieth, Johannes; Aulakh, Parminder; Ibrahim-Hashi, Hashi; Manchanda, Raghav; Nilsson, Per H; Mollnes, Tom Eirik; Bhattacharyya, Maitreyee; Islam, Mohammad M; Hinkula, Jorma; Slater, Nigel K H; Patra, Hirak K.
Afiliação
  • Zhu GH; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
  • Azharuddin M; Department of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
  • Islam R; Department of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway.
  • Rahmoune H; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
  • Deb S; Department of Biotechnology, Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata 700064, India.
  • Kanji U; Department of Biotechnology, Maulana Abul Kalam Azad University of Technology (MAKAUT), Kolkata 700064, India.
  • Das J; Department of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
  • Osterrieth J; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
  • Aulakh P; Institute for Manufacturing (IfM), University of Cambridge, Cambridge CB3 0FS, U.K.
  • Ibrahim-Hashi H; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
  • Manchanda R; Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, U.K.
  • Nilsson PH; Department of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway.
  • Mollnes TE; Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar 391 82, Sweden.
  • Bhattacharyya M; Department of Immunology, Oslo University Hospital, University of Oslo, Oslo 0372, Norway.
  • Islam MM; Research Laboratory, Nordland Hospital, Bodø, and Faculty of Health Sciences, K.G. Jebsen TREC, University of Tromsø, Tromsø 9037, Norway.
  • Hinkula J; Institute of Haematology and Transfusion Medicine, Calcutta Medical College, Calcutta 700073, India.
  • Slater NKH; Massachusetts Eye and Ear and Schepens Eye Research Institute, Dept of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, United States.
  • Patra HK; Department of Biomedical and Clinical Sciences (BKV), Linkoping University, Linkoping 581 83, Sweden.
ACS Appl Mater Interfaces ; 13(20): 23410-23422, 2021 May 26.
Article em En | MEDLINE | ID: mdl-33978409
ABSTRACT
Nanomedicine is seen as a potential central player in the delivery of personalized medicine. Biocompatibility issues of nanoparticles have largely been resolved over the past decade. Despite their tremendous progress, less than 1% of applied nanosystems can hit their intended target location, such as a solid tumor, and this remains an obstacle to their full ability and potential with a high translational value. Therefore, achieving immune-tolerable, blood-compatible, and biofriendly nanoparticles remains an unmet need. The translational success of nanoformulations from bench to bedside involves a thorough assessment of their design, compatibility beyond cytotoxicity such as immune toxicity, blood compatibility, and immune-mediated destruction/rejection/clearance profile. Here, we report a one-pot process-engineered synthesis of ultrasmall gold nanoparticles (uGNPs) suitable for better body and renal clearance delivery of their payloads. We have obtained uGNP sizes of as low as 3 nm and have engineered the synthesis to allow them to be accurately sized (almost nanometer by nanometer). The synthesized uGNPs are biocompatible and can easily be functionalized to carry drugs, peptides, antibodies, and other therapeutic molecules. We have performed in vitro cell viability assays, immunotoxicity assays, inflammatory cytokine analysis, a complement activation study, and blood coagulation studies with the uGNPs to confirm their safety. These can help to set up a long-term safety-benefit framework of experimentation to reveal whether any designed nanoparticles are immune-tolerable and can be used as payload carriers for next-generation vaccines, chemotherapeutic drugs, and theranostic agents with better body clearance ability and deep tissue penetration.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Materiais Biocompatíveis / Nanopartículas Metálicas / Ouro / Imunidade Inata Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Materiais Biocompatíveis / Nanopartículas Metálicas / Ouro / Imunidade Inata Idioma: En Ano de publicação: 2021 Tipo de documento: Article